Shaherin Basith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaherin Basith has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gwang Lee
Department of Molecular Science and Technology, Ajou University, Suwon, Korea
10 shared publications - Balachandran Manavalan
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University , Suwon 16419, Gyeonggi-do
7 shared publications - Ji Su Hwang
Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
3 shared publications - Minjun Kwon
Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
3 shared publications - Nimisha Pradeep George
Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
3 shared publications - Seok Gi Kim
Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea
3 shared publications
Latest Publications
- 17 August 2026
- Published by Wiley in Medicinal Research Reviews
Unraveling the Intricacies of G‐Protein‐Coupled Receptor Signaling in Cardiovascular Diseases: Novel Perspectives From Regulation to Therapeutic Targeting
G‐protein‐coupled receptors (GPCRs) represent a compelling intersection of structural biology, systems pharmacology, and clinical medicine. They function as essential molecular regulators of cardiovascular physiology, governing processes from the initiation of cardiac rhythm in the sinoatrial node to the regulation of vascular tone. Their widespread expression in cardiac and vascular tissues, combined with their ability to integrate diverse extracellular signals, positions GPCRs as key regulators of heart rate, contractility, vascular tone, inflammation, and metabolic homeostasis. Recent advances in GPCR structural biology, coupled with mechanistic insights into G‐protein‐ and β‐arrestin‐mediated signaling mechanisms, underscore their central role in both cardiovascular health and disease. Notably, dysregulation of GPCR signaling has emerged as a unifying mechanism across major cardiovascular diseases (CVDs), contributing to pathological remodeling, impaired contractile function, and maladaptive vascular responses. This review uniquely integrates GPCR structural biology, signaling dynamics, and mechanosensitive and biased signaling mechanisms within the cardiovascular system. We discuss the contributions of class A, class B, and other GPCR families to cardiovascular physiology and pathology emphasizing their relevance to the development of targeted interventions for hypertension, heart failure, arrhythmias, atherosclerosis, and related CVDs. Together, these insights establish a contemporary framework for advancing precision GPCR‐directed therapies in CVDs. By framing these developments within a mechanistic and translational context, the review offers a timely and clinically significant resource for both basic researchers and clinicians.
- 17 August 2026
- Published by Wiley in Medicinal Research Reviews
Unraveling the Intricacies of G‐Protein‐Coupled Receptor Signaling in Cardiovascular Diseases: Novel Perspectives From Regulation to Therapeutic Targeting
G‐protein‐coupled receptors (GPCRs) represent a compelling intersection of structural biology, systems pharmacology, and clinical medicine. They function as essential molecular regulators of cardiovascular physiology, governing processes from the initiation of cardiac rhythm in the sinoatrial node to the regulation of vascular tone. Their widespread expression in cardiac and vascular tissues, combined with their ability to integrate diverse extracellular signals, positions GPCRs as key regulators of heart rate, contractility, vascular tone, inflammation, and metabolic homeostasis. Recent advances in GPCR structural biology, coupled with mechanistic insights into G‐protein‐ and β‐arrestin‐mediated signaling mechanisms, underscore their central role in both cardiovascular health and disease. Notably, dysregulation of GPCR signaling has emerged as a unifying mechanism across major cardiovascular diseases (CVDs), contributing to pathological remodeling, impaired contractile function, and maladaptive vascular responses. This review uniquely integrates GPCR structural biology, signaling dynamics, and mechanosensitive and biased signaling mechanisms within the cardiovascular system. We discuss the contributions of class A, class B, and other GPCR families to cardiovascular physiology and pathology emphasizing their relevance to the development of targeted interventions for hypertension, heart failure, arrhythmias, atherosclerosis, and related CVDs. Together, these insights establish a contemporary framework for advancing precision GPCR‐directed therapies in CVDs. By framing these developments within a mechanistic and translational context, the review offers a timely and clinically significant resource for both basic researchers and clinicians.
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
CONTRA-IL6: an interpretable hybrid convolutional neural network and Transformer framework for accurate prediction of interleukin-6-inducing peptides using protein language models
Interleukin-6 (IL-6) is a key immunomodulatory cytokine implicated in diverse physiological processes and pathological conditions, including autoimmune diseases, cancers, and cytokine storms. Immunogenic peptides capable of inducing IL-6 expression are key modulators of host immune responses and represent promising candidates for therapeutic design and epitope-based vaccine development. However, experimental identification of IL-6-inducing peptides remains laborious and unsuitable for large-scale screening. Although existing computational approaches show promise, many often struggle to capture both global contextual semantics and local motif-level features essential for peptide immunogenicity. To address these limitations, we present CONTRA-IL6, a novel deep learning framework that integrates Transformer fusion and convolutional localization modules with stacked pretrained protein language model embeddings to predict IL-6-inducing peptides. Comprehensive benchmarking on an independent dataset demonstrates that CONTRA-IL6 achieves superior predictive performance over six state-of-the-art predictors. Notably, it achieves the highest Matthews correlation coefficient (MCC, 0.504) and F1 (0.549) and improves over the best-performing existing method by 3.2% in MCC and 4.3% in F1, demonstrating balanced and robust performance. Feature space visualizations (uniform manifold approximation and projection, kernel density estimation) showed clear class separation, while 1D gradient-weighted class activation mapping++ highlighted strong attention to specific C-terminal regions. Crucially, we moved beyond these attribution methods by employing in silico mutagenesis, which causally confirmed the functional importance and physicochemical constraints. Ablation studies further confirmed the synergistic contribution of global and local modules to model performance. CONTRA-IL6 offers a robust, scalable, and interpretable solution for immunoinformatics research. The standalone package is freely available at https://pypi.org/project/contra-il6/ to facilitate broader community use.
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
Open AccessCONTRA-IL6: an interpretable hybrid convolutional neural network and Transformer framework for accurate prediction of interleukin-6-inducing peptides using protein language models
Interleukin-6 (IL-6) is a key immunomodulatory cytokine implicated in diverse physiological processes and pathological conditions, including autoimmune diseases, cancers, and cytokine storms. Immunogenic peptides capable of inducing IL-6 expression are key modulators of host immune responses and represent promising candidates for therapeutic design and epitope-based vaccine development. However, experimental identification of IL-6-inducing peptides remains laborious and unsuitable for large-scale screening. Although existing computational approaches show promise, many often struggle to capture both global contextual semantics and local motif-level features essential for peptide immunogenicity. To address these limitations, we present CONTRA-IL6, a novel deep learning framework that integrates Transformer fusion and convolutional localization modules with stacked pretrained protein language model embeddings to predict IL-6-inducing peptides. Comprehensive benchmarking on an independent dataset demonstrates that CONTRA-IL6 achieves superior predictive performance over six state-of-the-art predictors. Notably, it achieves the highest Matthews correlation coefficient (MCC, 0.504) and F1 (0.549) and improves over the best-performing existing method by 3.2% in MCC and 4.3% in F1, demonstrating balanced and robust performance. Feature space visualizations (uniform manifold approximation and projection, kernel density estimation) showed clear class separation, while 1D gradient-weighted class activation mapping++ highlighted strong attention to specific C-terminal regions. Crucially, we moved beyond these attribution methods by employing in silico mutagenesis, which causally confirmed the functional importance and physicochemical constraints. Ablation studies further confirmed the synergistic contribution of global and local modules to model performance. CONTRA-IL6 offers a robust, scalable, and interpretable solution for immunoinformatics research. The standalone package is freely available at https://pypi.org/project/contra-il6/ to facilitate broader community use.
- Open Access
- 28 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 537
Integrative Peptide Drug Development: Chemical Engineering, AI-Driven Design, and Cell-Penetrating Peptides
Peptide therapeutics occupy a unique chemical space between small molecules and biologics, combining high target specificity with structural programmability and favorable safety profiles. Recent regulatory approvals and expanding clinical pipelines underscore the growing therapeutic and commercial relevance of peptide-based drugs. This review outlines chemical modification approaches and contemporary design strategies, and evaluates their impact on proteolytic stability, pharmacokinetics, membrane permeability, and target engagement. We then highlight recent advances in artificial intelligence (AI)-guided peptide drug design, including machine learning models, protein language models, and generative architectures that enable high-throughput activity prediction, property optimization, and de novo sequence generation. These approaches collectively accelerate the traditional discovery–design–validation cycle while reducing experimental attrition through data-driven, structure-informed modeling frameworks. Among these applications, AI also enables the rational design of cell-penetrating peptides (CPPs) to enhance intracellular delivery and biological activity. Building on these methodological advances, we further examine their application to peptide therapeutics, with particular emphasis on AI-based predictive models for CPPs as well as on therapeutic applications within the central nervous and pulmonary systems. We conclude by outlining future perspectives and emphasize that the systematic integration of AI-enabled sequence design with rational chemical engineering and advanced delivery technologies, supported by rigorous experimental validation, will be critical for developing robust and clinically durable peptide-based medicines.
- 28 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 537
Open AccessIntegrative Peptide Drug Development: Chemical Engineering, AI-Driven Design, and Cell-Penetrating Peptides
Peptide therapeutics occupy a unique chemical space between small molecules and biologics, combining high target specificity with structural programmability and favorable safety profiles. Recent regulatory approvals and expanding clinical pipelines underscore the growing therapeutic and commercial relevance of peptide-based drugs. This review outlines chemical modification approaches and contemporary design strategies, and evaluates their impact on proteolytic stability, pharmacokinetics, membrane permeability, and target engagement. We then highlight recent advances in artificial intelligence (AI)-guided peptide drug design, including machine learning models, protein language models, and generative architectures that enable high-throughput activity prediction, property optimization, and de novo sequence generation. These approaches collectively accelerate the traditional discovery–design–validation cycle while reducing experimental attrition through data-driven, structure-informed modeling frameworks. Among these applications, AI also enables the rational design of cell-penetrating peptides (CPPs) to enhance intracellular delivery and biological activity. Building on these methodological advances, we further examine their application to peptide therapeutics, with particular emphasis on AI-based predictive models for CPPs as well as on therapeutic applications within the central nervous and pulmonary systems. We conclude by outlining future perspectives and emphasize that the systematic integration of AI-enabled sequence design with rational chemical engineering and advanced delivery technologies, supported by rigorous experimental validation, will be critical for developing robust and clinically durable peptide-based medicines.
- Open Access
- 3 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110668
EnsemPred-ACP: Combining machine and deep learning to improve anticancer peptide prediction
- 3 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110668
Open AccessEnsemPred-ACP: Combining machine and deep learning to improve anticancer peptide prediction
- Open Access
- 20 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 195, 110590
CPPpred-En: Ensemble framework integrating a protein language model and conventional features for highly accurate cell-penetrating peptide prediction
- 20 June 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 195, 110590
Open AccessCPPpred-En: Ensemble framework integrating a protein language model and conventional features for highly accurate cell-penetrating peptide prediction
- 23 October 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 183, 109297
mHPpred: Accurate identification of peptide hormones using multi-view feature learning
- 23 October 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 183, 109297
mHPpred: Accurate identification of peptide hormones using multi-view feature learning
- 15 November 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 168, 107688
Unveiling local and global conformational changes and allosteric communications in SOD1 systems using molecular dynamics simulation and network analyses
- 15 November 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 168, 107688
Unveiling local and global conformational changes and allosteric communications in SOD1 systems using molecular dynamics simulation and network analyses
- Open Access
- 30 September 2021
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 23 (1)
Comparative analysis of machine learning-based approaches for identifying therapeutic peptides targeting SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has impacted public health as well as societal and economic well-being. In the last two decades, various prediction algorithms and tools have been developed for predicting antiviral peptides (AVPs). The current COVID-19 pandemic has underscored the need to develop more efficient and accurate machine learning (ML)-based prediction algorithms for the rapid identification of therapeutic peptides against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Several peptide-based ML approaches, including anti-coronavirus peptides (ACVPs), IL-6 inducing epitopes and other epitopes targeting SARS-CoV-2, have been implemented in COVID-19 therapeutics. Owing to the growing interest in the COVID-19 field, it is crucial to systematically compare the existing ML algorithms based on their performances. Accordingly, we comprehensively evaluated the state-of-the-art IL-6 and AVP predictors against coronaviruses in terms of core algorithms, feature encoding schemes, performance evaluation metrics and software usability. A comprehensive performance assessment was then conducted to evaluate the robustness and scalability of the existing predictors using well-constructed independent validation datasets. Additionally, we discussed the advantages and disadvantages of the existing methods, providing useful insights into the development of novel computational tools for characterizing and identifying epitopes or ACVPs. The insights gained from this review are anticipated to provide critical guidance to the scientific community in the rapid design and development of accurate and efficient next-generation in silico tools against SARS-CoV-2.
- 30 September 2021
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 23 (1)
Open AccessComparative analysis of machine learning-based approaches for identifying therapeutic peptides targeting SARS-CoV-2
Coronavirus disease 2019 (COVID-19) has impacted public health as well as societal and economic well-being. In the last two decades, various prediction algorithms and tools have been developed for predicting antiviral peptides (AVPs). The current COVID-19 pandemic has underscored the need to develop more efficient and accurate machine learning (ML)-based prediction algorithms for the rapid identification of therapeutic peptides against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Several peptide-based ML approaches, including anti-coronavirus peptides (ACVPs), IL-6 inducing epitopes and other epitopes targeting SARS-CoV-2, have been implemented in COVID-19 therapeutics. Owing to the growing interest in the COVID-19 field, it is crucial to systematically compare the existing ML algorithms based on their performances. Accordingly, we comprehensively evaluated the state-of-the-art IL-6 and AVP predictors against coronaviruses in terms of core algorithms, feature encoding schemes, performance evaluation metrics and software usability. A comprehensive performance assessment was then conducted to evaluate the robustness and scalability of the existing predictors using well-constructed independent validation datasets. Additionally, we discussed the advantages and disadvantages of the existing methods, providing useful insights into the development of novel computational tools for characterizing and identifying epitopes or ACVPs. The insights gained from this review are anticipated to provide critical guidance to the scientific community in the rapid design and development of accurate and efficient next-generation in silico tools against SARS-CoV-2.